Free Webinar - The Early Access Masterclass: translate early access into wider access
How best to align market access and R&D? We know, it’s been a question of discussion for years now, yet it remains a heated debate.
Should we be aiming for early, phased access? Should we continue to emphasise the focus of involving access departments early in the life cycle to maximise launch? How do we gain the benefits of maximising launch options without adding significant delays and development costs?
Sign-up for our latest webinar: https://goo.gl/Sb992z on Thursday 25th Jan, and kick of 2018 in the right way, as we bring together key industry leaders to discuss the best path forward for 2018 and beyond.
Expert panellists include:
• Pernille Storm, Global Market Access Director Neurology, Lundbeck
• Simon Shohet, Senior Director, Market Access and Pricing, Ipsen
• Michael Lees, Head of Value, Evidence & Portfolio Strategy (EUCAN), Takeda
Click here to sign-up: https://goo.gl/Sb992z
And also remember, all sign-ups receive the recordings so don’t worry if you can’t make the timings.
Should we be aiming for early, phased access? Should we continue to emphasise the focus of involving access departments early in the life cycle to maximise launch? How do we gain the benefits of maximising launch options without adding significant delays and development costs?
Sign-up for our latest webinar: https://goo.gl/Sb992z on Thursday 25th Jan, and kick of 2018 in the right way, as we bring together key industry leaders to discuss the best path forward for 2018 and beyond.
Expert panellists include:
• Pernille Storm, Global Market Access Director Neurology, Lundbeck
• Simon Shohet, Senior Director, Market Access and Pricing, Ipsen
• Michael Lees, Head of Value, Evidence & Portfolio Strategy (EUCAN), Takeda
Click here to sign-up: https://goo.gl/Sb992z
And also remember, all sign-ups receive the recordings so don’t worry if you can’t make the timings.
